What risks can result when drug approvals are accelerated?

When regulatory agencies prioritize the rapid approval of new drugs to address unmet medical needs, the primary risk is that the resulting products may exhibit levels of toxicity that the public finds unacceptable.1

Accelerated approval processes—such as those used for cancer or AIDS medications—often rely on surrogate endpoints rather than comprehensive clinical results. By streamlining these requirements, there is a greater possibility that severe adverse reactions or toxicities remain unidentified before the drug reaches the general population.1234

Because clinical trials involve a limited number of participants, they may fail to detect rare but serious side effects that only appear once a drug is used by a much larger, diverse population. While these expedited pathways are intended to provide life-saving treatments to those in need, they inherently involve a trade-off between speed and the depth of safety data available at the time of marketing. Consequently, drug regulation remains a delicate balance, often shifting toward more restrictive oversight following drug-related catastrophes and toward more lenient policies when public demand for new therapies is high.412